BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

15 articles for DR Alessi

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.EBI
Glaxosmithkline
Brain Penetrant LRRK2 Inhibitor.EBI
TBA
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.EBI
University of Dundee
The selectivity of protein kinase inhibitors: a further update.EBI
University of Dundee
Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.EBI
University of Dundee
Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.EBI
University of Dundee
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.EBI
University of Dundee
Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.EBI
Harvard Medical School
Development of a highly potent and selective degrader of LRRK2.EBI
Harvard University
Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins.EBI
University of Dundee
Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1.EBI
Lifearc
Alkynyl alcohols and methods of useBDB
Genentech
Substituted isoxazoles for treating cancerBDB
Epizyme
Quinazoline heterocyclic compound as EGFR kinase inhibitor and preparation and application thereofBDB
Beijing Scitech-Mq Pharmaceuticals